---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-031673"
form_type: "8-K"
ticker: "BFRI"
cik: "0001858685"
company_name: "Biofrontera Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T21:27:43.499216+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biofrontera Q3 rev flat at $4.3M, net loss narrows; guides 2022 rev growth 24-31%

## Summary
- Q3 revenue $4.3M (flat YoY); net loss $2.6M ($0.11/shr) vs $16.0M loss in Q3 2021.
- 9-month revenue $18.5M (+24% YoY); net income $2.1M ($0.11 diluted) vs $23.2M loss in 9M 2021.
- Cash $27.5M (Sep 30, 2022) vs $24.5M (Dec 31, 2021); raised $4.3M net from warrant exercises and private placement.
- FY 2022 revenue guidance revised to 24-31% growth over 2021, citing seasonal strength in Q1 and Q4.
- Named Fred Leffler as CFO and Gerard DiGirolamo as National Sales Director.

## SEC filing metadata
- accession: 0001493152-22-031673
- form_type: 8-K
- ticker: BFRI
- cik: 0001858685
- company_name: Biofrontera Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858685/000149315222031673/0001493152-22-031673-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858685/000149315222031673/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-031673
- JSON: https://secwatch.observer/filing/0001493152-22-031673.json
- Plain text: https://secwatch.observer/filing/0001493152-22-031673.txt

## Key facts
- Earnings Releases
  Biofrontera Inc. reported Fiscal year ending December 31, 2022 results: revenue total revenues for 2022 to increase between 24% and 31% compared with 2021. Guidance initiated.
  - Period: Fiscal year ending December 31, 2022
  - Revenue: total revenues for 2022 to increase between 24% and 31% compared with 2021
  - Guidance: initiated
  - Result: guidance update
  source text: With year-to-date revenues up 24%, we expect total revenues for 2022 to increase between 24% and 31% compared with 2021, inclusive of seasonal strength in the first and fourth quarters.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858685/000149315222031673/0001493152-22-031673-index.htm
- Earnings Releases
  Biofrontera Inc. reported Third quarter ended September 30, 2022 results: revenue Total revenues $4.3 million, net income Net loss $2.6 million, EPS $0.11 per share.
  - Period: Third quarter ended September 30, 2022
  - Revenue: Total revenues $4.3 million
  - Net income: Net loss $2.6 million
  - EPS: $0.11 per share
  - Result: reported results
  source text: Total revenues for the third quarter of 2022 of $4.3 million were consistent with the third quarter of 2021. Total operating expenses were $8.0 million for the third quarter of 2022, compared with $20.4 million for the third quarter of 2021. Cost of revenues decreased by 3% primarily due to lower Ameluz sales. Selling, general and administrative expenses decreased by $9.3 million, or 54%, compared with the prior year primarily due to a one-time legal settlement expense in 2021, partially offset by higher business insurance and headcount costs as a result of resumed hiring in 2022. Net loss for the third quarter of 2022 was $2.6 million, or $0.11 per share, compared with a net loss of $16.0 million, or $2.00 per share, for the third quarter of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858685/000149315222031673/0001493152-22-031673-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.